Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
NCT ID: NCT02697773
Last Updated: 2021-05-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
698 participants
INTERVENTIONAL
2016-01-21
2018-05-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tanezumab in Osteoarthritis Of The Hip
NCT00744471
Tanezumab In Osteoarthritis Of The Hip Or Knee
NCT00985621
Tanezumab in Osteoarthritis of the Hip or Knee (2)
NCT00863304
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
NCT00809354
Tanezumab In Osteoarthritis Of The Knee (2)
NCT00830063
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
placebo administered subcutaneously at day 0 and week 8
Placebo
Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
Tanezumab 2.5 mg
tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
Tanezumab 2.5 mg
Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
Tanezumab 2.5mg/5mg
tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
Tanezumab 2.5mg/5mg
Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
Tanezumab 2.5 mg
Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
Tanezumab 2.5mg/5mg
Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented history that subject tried the following medications and had insufficient pain relief or is cannot take or tolerate them: acetaminophen, NSAIDs and either tramadol or opioids
* Meet the protocol requirements for pain at screening and pain, physical function and patient global assessment of osteoarthritis at baseline
* Willing to discontinue all pain medications except study medication and rescue medication during the course of the study and use those as directed per protocol
* Women able to have children must agree to use 2 forms of contraception during the study
Exclusion Criteria
* History of diseases other than osteoarthritis in a shoulder, hip or knee (example, rheumatoid arthritis, gout, joint infections, osteonecrosis)
* Patients with x-ray showing joint conditions such as osteonecrosis (dead bone) or certain types of fractures
* Patients who have had significant trauma or surgery to a knee, hip or shoulder within the previous year
* Planned surgical procedure during the study
* Patients who are largely or wholly incapacitated (example bedridden or confined to a wheelchair, permitting little or no self-care)
* Patients who would be unwilling or unable to undergo joint replacement surgery if one eventually became necessary
* Patients with significant conditions other than osteoarthritis that could interfere with assessment of pain in the joints (example fibromyalgia, lupus erythematosus)
* Patients with significant heart, neurological or psychiatric diseases
* Patients who had cancer other than certain skin cancers within the past 5 years
* Patients with alcohol, analgesic (pain medications) or drug abuse within the past 2 years
* Women who are pregnant, breast-feeding or intending to become pregnant or breast-feed during the course of the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Orthopaedic Surgeons
Birmingham, Alabama, United States
Cahaba Research, Inc.
Birmingham, Alabama, United States
Arizona Research Center
Phoenix, Arizona, United States
Clinical Research Institute of Arizona, LLC
Surprise, Arizona, United States
Tucson Orthopaedic Institute
Tucson, Arizona, United States
University of Arizona Clinical and Translational Science Research Center
Tucson, Arizona, United States
Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States
Advanced Research Center, Inc
Anaheim, California, United States
Medvin Clinical Research
Covina, California, United States
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
Fullerton, California, United States
Irvine Center for Clinical Research
Irvine, California, United States
Robert L Freed, M.D., F.A.C.R / Clinical Interventions Research Institute
Irvine, California, United States
Providence Clinical Research
North Hollywood, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
California Research Foundation
San Diego, California, United States
Inland Rheumatology Clinical Trials, Inc.
Upland, California, United States
Alpine Clinical Research Center
Boulder, Colorado, United States
New England Research Associates, LLC
Bridgeport, Connecticut, United States
Stamford Therapeutics Consortium
Stamford, Connecticut, United States
Clinical Physiology Associates
Fort Myers, Florida, United States
Eastern Research, Inc.
Hialeah, Florida, United States
South Florida Research Center, Inc.
Miami, Florida, United States
New Horizon Research Center
Miami, Florida, United States
Miami Dade Medical Research Institute, LLC
Miami, Florida, United States
Compass Research, LLC
Orlando, Florida, United States
Ormond Beach Clinical Research
Ormond Beach, Florida, United States
Phoenix Clinical Research, LLC
Tamarac, Florida, United States
Bioclinica Research
The Villages, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Center for Advanced Research & Education (CARE)
Gainesville, Georgia, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
Medex Healthcare Research Inc
Chicago, Illinois, United States
Chicago Clinical Research Institute, Inc.
Chicago, Illinois, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Great Lakes Clinical Trials
Chicago, Illinois, United States
Investigators Research Group, LLC
Brownsburg, Indiana, United States
Integrated Clinical Trial Services, Inc.
West Des Moines, Iowa, United States
Professional Research Network of Kansas, LLC
Wichita, Kansas, United States
George Stanley Walker, MD
New Orleans, Louisiana, United States
Tristan Medical Enterprises, PC dba Regeneris Medical
North Attleboro, Massachusetts, United States
Michigan Orthopaedic & Spine Surgeons
Rochester Hills, Michigan, United States
Arthritis and Osteoporosis Treatment and Research Center
Flowood, Mississippi, United States
Office Of Stephen H. Miller, M.D.
Las Vegas, Nevada, United States
Arthritis And Osteoporosis Associates
Freehold, New Jersey, United States
New Mexico Clinical Research & Osteoporosis Center, Inc.
Albuquerque, New Mexico, United States
Drug Trials America
Hartsdale, New York, United States
Wake Research Associates, LLC
Raleigh, North Carolina, United States
Plains Clinical Research Center, LLC
Fargo, North Dakota, United States
Prestige Clinical Research
Franklin, Ohio, United States
AC Clinical Research
Tiffin, Ohio, United States
NPC Research
Oklahoma City, Oklahoma, United States
Hillcrest Clinical Research
Oklahoma City, Oklahoma, United States
University Orthopedics Center
State College, Pennsylvania, United States
Palmetto Clinical Trial Services, LLC
Greenville, South Carolina, United States
Health Concepts
Rapid City, South Dakota, United States
Quality Medical Research
Nashville, Tennessee, United States
KRK Medical Research
Arlington, Texas, United States
Tekton Research, Inc
Austin, Texas, United States
Urgent Care MD's
Baytown, Texas, United States
Arthritis Care and Diagnostic Center
Dallas, Texas, United States
T&R Clinic, PA
Fort Worth, Texas, United States
Centex Studies, Inc.
Houston, Texas, United States
BI Research Center
Houston, Texas, United States
The Pain Relief Center
Plano, Texas, United States
Center for Arthritis and Rheumatic Diseases
Chesapeake, Virginia, United States
Spectrum Medical, Inc
Danville, Virginia, United States
National Clinical Research - Richmond, Inc
Richmond, Virginia, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Aggarwal and Associates Limited
Brampton, Ontario, Canada
Manna Research Inc. (Burlington south)
Burlington, Ontario, Canada
Dawson Road Medical Centre
Guelph, Ontario, Canada
Adachi Medicine Professional Corporation
Hamilton, Ontario, Canada
K-W Musculoskeletal Research Inc.
Kitchener, Ontario, Canada
Western Center for Public Health and Family Medicine
London, Ontario, Canada
Malton Medical Centre
Mississauga, Ontario, Canada
Rebecca Medical Associates
Oakville, Ontario, Canada
King Street Medical Clinic
Oshawa, Ontario, Canada
Bluewater Clinical Research Group
Sarnia, Ontario, Canada
Diex Recheche Montreal, Inc.
Montreal, Quebec, Canada
Recherche Clinique Sigma inc
Québec, Quebec, Canada
Diex Recherche Quebec Inc.
Québec, Quebec, Canada
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc.
Québec, Quebec, Canada
Centre de recherche Saint-Louis
Québec, Quebec, Canada
Alpha Recherche Clinique
Québec, Quebec, Canada
Diex Research Sherbrooke Inc.
Sherbrooke, Quebec, Canada
Puerto Rico Medical Research Inc.
Ponce, PR, Puerto Rico
Mindful Medical Research
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schnitzer TJ, Conaghan PG, Berenbaum F, Abraham L, Cappelleri JC, Bushmakin AG, Viktrup L, Yang R, Brown MT. Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis. Adv Rheumatol. 2024 Apr 22;64(1):31. doi: 10.1186/s42358-024-00358-y.
Guermazi A, Roemer FW, Kompel AJ, Diaz LE, Crema MD, Brown MT, Hickman A, Pixton GC, Viktrup L, Fountaine RJ, Burr A, Sherlock SP, West CR. Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With Osteoarthritis. Osteoarthr Imaging. 2022 Sep-Dec;2(3-4):100082. doi: 10.1016/j.ostima.2022.100082. Epub 2022 Nov 15.
Ren J, Bushmakin AG, Cislo PR, Abraham L, Cappelleri JC, Dworkin RH, Farrar JT. Meaningful within-patient change for clinical outcome assessments: model-based approach versus cumulative distribution functions. J Biopharm Stat. 2025 Aug;35(5):826-838. doi: 10.1080/10543406.2023.2281575. Epub 2023 Nov 20.
Carrino JA, McAlindon TE, Schnitzer TJ, Guermazi A, Hochberg MC, Conaghan PG, Brown MT, Burr A, Fountaine RJ, Pixton GC, Viktrup L, Verburg KM, West CR. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab. Osteoarthritis Cartilage. 2023 Dec;31(12):1612-1626. doi: 10.1016/j.joca.2023.08.010. Epub 2023 Aug 29.
Shoji S, Suzuki A, Nouri P, Cai CH, Gaitonde P, Marshall S. Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor. CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1358-1370. doi: 10.1002/psp4.13015. Epub 2023 Jul 31.
Brown MT, Cornblath DR, Koltzenburg M, Gorson KC, Hickman A, Pixton GC, Gaitonde P, Viktrup L, West CR. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clin Drug Investig. 2023 Jul;43(7):551-563. doi: 10.1007/s40261-023-01286-3. Epub 2023 Jul 18.
Colloca L, Dworkin RH, Farrar JT, Tive L, Yang J, Viktrup L, Dasic G, West CR, Whalen E, Brown MT, Gilbert SA, Verburg KM. Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials. Clin Pharmacol Ther. 2023 Apr;113(4):878-886. doi: 10.1002/cpt.2842. Epub 2023 Jan 31.
Hunter DJ, Schnitzer TJ, Hall J, Semel D, Davignon I, Cappelleri JC, Bushmakin AG, Abraham L. Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab. Osteoarthr Cartil Open. 2022 Jul 2;4(3):100294. doi: 10.1016/j.ocarto.2022.100294. eCollection 2022 Sep.
Atkinson J, Edwards RA, Bonfanti G, Barroso J, Schnitzer TJ. A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis. Adv Ther. 2023 Jan;40(1):252-264. doi: 10.1007/s12325-022-02336-6. Epub 2022 Oct 27.
Mease P, Kuritzky L, Wright WL, Mallick-Searle T, Fountaine R, Yang R, Sadrarhami M, Faison W, Johnston E, Viktrup L. Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials. Curr Med Res Opin. 2022 Nov;38(11):1909-1922. doi: 10.1080/03007995.2022.2113689. Epub 2022 Aug 28.
Schnitzer TJ, Bonfanti G, Atkinson J, Donevan S, Viktrup L, Barroso J, Whalen E, Edwards RA. Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis. Adv Ther. 2022 Oct;39(10):4742-4756. doi: 10.1007/s12325-022-02290-3. Epub 2022 Aug 12.
Conaghan PG, Dworkin RH, Schnitzer TJ, Berenbaum F, Bushmakin AG, Cappelleri JC, Viktrup L, Abraham L. WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee. J Rheumatol. 2022 Jun;49(6):615-621. doi: 10.3899/jrheum.210543. Epub 2022 Mar 1.
Conaghan PG, Abraham L, Viktrup L, Cislo P. Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis. BMC Musculoskelet Disord. 2022 Feb 1;23(1):106. doi: 10.1186/s12891-022-05029-x.
Berenbaum F, Schnitzer T, Kivitz A, Viktrup L, Johnston E, Yang R, Whalen E, Tive L, Semel D. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials. Int J Clin Pract. 2021 Dec;75(12):e14975. doi: 10.1111/ijcp.14975. Epub 2021 Oct 21.
Berenbaum F, Schnitzer TJ, Kivitz AJ, Viktrup L, Hickman A, Pixton G, Brown MT, Davignon I, West CR. General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials. Arthritis Care Res (Hoboken). 2022 Jun;74(6):918-928. doi: 10.1002/acr.24637. Epub 2022 Mar 25.
Schnitzer TJ, Khan A, Bessette L, Davignon I, Brown MT, Pixton G, Prucka WR, Tive L, Viktrup L, West CR. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study. Semin Arthritis Rheum. 2020 Jun;50(3):387-393. doi: 10.1016/j.semarthrit.2020.03.004. Epub 2020 Mar 19.
Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. JAMA. 2019 Jul 2;322(1):37-48. doi: 10.1001/jama.2019.8044.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-002222-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
OA TITRATION STUDY
Identifier Type: OTHER
Identifier Source: secondary_id
A4091056
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.